Planning and evaluation activities have played a key role in the growth and steady improvement of KUCC. Multiple internal committees including KUCC Leadership Council and Associate Directors Council guide the planning and evaluation process under the leadership of Director Jensen and in coordination with the External Advisory Board (EAB). The EAB serves a critical role in providing external oversight of planning and evaluation of KUCC vision, direction, leadership, research programs, and supporting infrastructure. The EAB was selected by KUCC leadership to match our research programs, shared resources and administrative components. The EAB has made numerous major recommendations such as defining the relationship between the KU Hospital and KUCC, increasing the number of patients on therapeutic trials, suggesting a timeline for the PSO application, suggesting ways to tighten membership criteria, expanding the number of NCI funded investigators, better integrating with the Stowers Institute for Medical Research, integrating clinicians into the Drug Discovery, Delivery and Experimental Therapeutics Program, and improving the KUCC website. KUCC Leadership Council promotes scientific interactions between the basic, translational, and clinical elements of the Center, plans development of the research programs, leverages KUCC resources for maximum benefit, and oversees activities of KUCC programs. The Associate Directors Council evaluates cross-program activities including symposia, seminars and conferences, allocations of pre-and post-doctoral trainee stipends and KUCC pilot research grants, and new research membership applications as well as conducts an annual review of membership. Each year the Associate Directors Council reviews the progress of the research programs, shared resources and administrative functions of KUCC. The KUCC-ADC makes final recommendations to the Director on practically all issues including budget, resource allocation, membership, space, leadership appointments, and strategic direction. The MCA Partners Advisory Board promotes collaboration of key hospitals and research institutions in the areas of research and education and advises the Cancer Center Director on the impact of KUCC in the community.
Planning and evaluation activities have clearly been an essential component of our continued and steady improvement over the last seven years and will continue to play a critical role in the future. KUCC's External Advisory Board and key internal advisory groups have played important roles in this activity and this has resulted in a vigorous and robust process of envisioning our potential, thoughtful reflection, and proactive change management.
|Ledgerwood, Levi G; Kumar, Dhruv; Eterovic, Agda Karina et al. (2016) The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7:27185-98|
|Reed, Gregory A; Schiller, Gary J; Kambhampati, Suman et al. (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med 5:3031-3040|
|Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89|
|Parsel, S M; Grandis, J R; Thomas, S M (2016) Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 35:3217-26|
|(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675|
|Mitchell, Julie L; Seng, Amara; Yankee, Thomas M (2016) Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes. Immunology 149:400-412|
|Hamilton-Reeves, Jill M; Bechtel, Misty D; Hand, Lauren K et al. (2016) Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. Eur Urol 69:389-92|
|Kurahara, Hiroshi; Bohl, Christopher; Natsugoe, Shoji et al. (2016) Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Int J Cancer 139:628-38|
|Jiang, Yu; Guarino, Peter; Ma, Shuangge et al. (2016) Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application. Trials 17:336|
|(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401|
Showing the most recent 10 out of 93 publications